Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF

Catalog # Availability Size / Price Qty
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (24)
Supplemental Products
Reviews (1)

Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF Summary

Product Specifications

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 3-15 ng/mL in the presence of 12 ng/mL of cross-linked Recombinant Human TRAIL/TNFSF10 (Catalog #s 375-TL and MAB050).
Mouse myeloma cell line, NS0-derived mouse Osteoprotegerin/TNFRSF11B protein
Mouse OPG
Glu22-Leu401 (Gln138Arg)
Accession # Q6PI12
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
70.9 kDa (monomer)
85-95 kDa, reducing conditions

Product Datasheets

You must select a language.



Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.


Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Background: Osteoprotegerin/TNFRSF11B

Osteoprotegerin (OPG), also called OCIF (osteoclastogenesis inhibitory factor) is a secreted 55-60 kDa protein that regulates bone density (1-3). As a member of the tumor necrosis factor receptor (TNFR) superfamily of proteins, it is designated TNFRSF11B (1-4). Mouse OPG cDNA encodes 401 amino acids (aa) including a 21 aa signal peptide and a 380 aa mature soluble protein with four TNFR domains, two death domains and a heparin‑binding region (4). The cysteine‑rich TNFR domains are essential for ligand interaction, while a cysteine at the C‑terminus mediates homodimerization (4). Mature mouse OPG shares 86%, 94%, 86%, 86% and 83% amino acid sequence identity with human, rat, equine, canine and bovine OPG, respectively. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts and endothelial cells (1, 2, 5, 7). Regulation of its expression by estrogen, parathyroid hormone and cytokines is complex and changes with age (2). OPG has been called a decoy receptor for the TNF superfamily ligands, TRANCE (tumor necrosis factor‑related activation‑induced cytokine), also called RANK L (receptor activator of NF kappa B ligand), and TRAIL (TNF‑related apoptosis‑inducing ligand), which also bind TNF family receptors RANK and TRAIL receptors 1-4, respectively (2, 6). TRAIL decreases the release of OPG from cells that express it, while OPG inhibits TRAIL‑induced apoptosis (5, 6). Expression of RANK L on the cell surface, and thus its ability to stimulate osteoclastogenesis, is regulated by OPG by intracellular and extracellular mechanisms (7). Within osteoblasts, interaction of the basic domain of OPG with RANK L in the Golgi inhibits RANK L secretion (7). Extracellularly, OPG binding to RANK L results in clathrin‑mediated internalization and degradation of both proteins (7, 8). Binding of OPG by syndecan‑1 heparin sulfates on multiple myeloma cells also results in OPG internalization and degradation, contributing to bone loss (8, 9). OPG deficiency can cause juvenile Paget’s disease in humans, and insufficient OPG to balance with RANK L and RANK can produce osteoporosis and vascular calcification in both mice and humans (2, 10, 11).

  1. Simonet, W.S. et al. (1997) Cell 89:309.
  2. Trouvin, A-P. and V. Goeb 2010) Clin. Interv. Aging 5:345.
  3. Yasuda, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:3597.
  4. Yamaguchi, K. et al. (1998) J. Biol. Chem. 273:5117.
  5. Corallini, F. et al. (2010) J. Cell. Physiol. Dec. 6 [Epub ahead of print].
  6. Emery, J.G. et al. (1998) J. Biol. Chem. 273:14363.
  7. Aoki, S. et al. (2010) J. Bone Miner. Res. 25:1907.
  8. Tat, S.K. et al. (2006) Bone 39:706.
  9. Standal, T. et al. (2002) Blood 100:3002.
  10. Whyte, M.P. et al. (2002) N. Engl. J. Med. 347:175.
  11. Van Campenhout, A. and J. Golledge (2009) Atherosclerosis 204:321.
Entrez Gene IDs
4982 (Human); 18383 (Mouse)
Alternate Names
OCIF; OCIFMGC29565; OPG; OPGtumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; TNFRSF11B; TR1; tumor necrosis factor receptor superfamily, member 11b

Citations for Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

24 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. The Mechanism of Osteoprotegerin-Induced Osteoclast Pyroptosis In Vitro
    Authors: J Zhu, Y Ma, J Wang, Y Wang, W Ali, H Zou, H Zhao, X Tong, R Song, Z Liu
    International Journal of Molecular Sciences, 2023-01-12;24(2):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  2. Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes
    Authors: JM Kim, YS Yang, J Xie, O Lee, J Kim, J Hong, B Boldyreff, O Filhol, H Chun, MB Greenblatt, G Gao, JH Shim
    Cell Death and Differentiation, 2022-02-15;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling
    Authors: MS AlQranei, LT Senbanjo, H Aljohani, T Hamza, MA Chellaiah
    BMC immunology, 2021-03-25;22(1):23.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  4. RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy
    Authors: M Paolino, R Koglgruber, SJF Cronin, I Uribesalgo, E Rauscher, J Harreiter, M Schuster, D Bancher-To, B Pranjic, M Novatchkov, JP Fededa, AJ White, V Sigl, S Dekan, T Penz, C Bock, L Kenner, GA Holländer, G Anderson, A Kautzky-Wi, JM Penninger
    Nature, 2020-12-23;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  5. Overexpression of c-Fos reverses osteoprotegerin-mediated suppression of osteoclastogenesis by increasing the Beclin1-induced autophagy
    Authors: X Tong, M Chen, R Song, H Zhao, J Bian, J Gu, Z Liu
    Journal of Cellular and Molecular Medicine, 2020-12-04;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  6. Osteoprotegerin is More than a Possible Serum Marker in Liver Fibrosis: A Study into its Function in Human and Murine Liver
    Authors: A Adhyatmika, L Beljaars, KSS Putri, H Habibie, CE Boorsma, C Reker-Smit, T Luangmonko, B Guney, A Haak, KA Mangnus, E Post, K Poelstra, K Ravnskjaer, P Olinga, BN Melgert
    Pharmaceutics, 2020-05-21;12(5):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Tissue Culture
  7. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1
    Authors: T Hasegawa, J Kikuta, T Sudo, Y Matsuura, T Matsui, S Simmons, K Ebina, M Hirao, D Okuzaki, Y Yoshida, A Hirao, VV Kalinichen, K Yamaoka, T Takeuchi, M Ishii
    Nat. Immunol., 2019-11-18;20(12):1631-1643.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  8. Role of osteoprotegerin in the regulation of dental epithelial?mesenchymal signaling during tooth development
    Authors: X Gao, J Zheng, S Tu, B Cai, R Zeng, L Xiang
    Mol Med Rep, 2019-08-07;20(4):3035-3042.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Bioassay
  9. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy
    Authors: SS Dufresne, A Boulanger-, S Bossé, A Argaw, D Hamoudi, L Marcadet, D Gamu, VA Fajardo, H Yagita, JM Penninger, A Russell Tu, J Frenette
    Acta Neuropathol Commun, 2018-04-24;6(1):31.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  10. Paracrine osteoprotegerin and ?-catenin stabilization support synovial sarcomagenesis in periosteal cells
    Authors: JJ Barrott, BE Illum, H Jin, ML Hedberg, Y Wang, A Grossmann, M Haldar, MR Capecchi, KB Jones
    J. Clin. Invest., 2017-11-20;0(0):.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  11. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
    Authors: S Bernardi, B Toffoli, F Bossi, R Candido, E Stenner, R Carretta, F Barbone, B Fabris
    BMC Nephrol, 2017-07-06;18(1):219.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  12. Neural crest-mediated bone resorption is a determinant of species-specific jaw length.
    Authors: Ealba E, Jheon A, Hall J, Curantz C, Butcher K, Schneider R
    Dev Biol, 2015-10-21;408(1):151-63.
    Species: Avian - Quail, Duck
    Sample Types: In Vivo
    Applications: In Vivo
  13. A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
    Authors: Matsushita M, Ozaki Y, Hasegawa Y, Terada F, Tabata N, Shiheido H, Yanagawa H, Oikawa T, Matsuo K, Du W, Yamada T, Hozumi M, Ichikawa D, Hattori Y
    PLoS ONE, 2015-01-24;10(1):e0116135.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  14. SH3BP2 cherubism mutation potentiates TNF-alpha-induced osteoclastogenesis via NFATc1 and TNF-alpha-mediated inflammatory bone loss.
    Authors: Mukai T, Ishida S, Ishikawa R, Yoshitaka T, Kittaka M, Gallant R, Lin Y, Rottapel R, Brotto M, Reichenberger E, Ueki Y
    J Bone Miner Res, 2014-12-01;29(12):2618-35.
    Species: Mouse
    Sample Types: Recombinant Protein
    Applications: Neutralization
  15. Age-related marrow adipogenesis is linked to increased expression of RANKL.
    Authors: Takeshita S, Fumoto T, Naoe Y, Ikeda K
    J Biol Chem, 2014-04-21;289(24):16699-710.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  16. An inducible, ligand-independent receptor activator of NF-kappaB gene to control osteoclast differentiation from monocytic precursors.
    Authors: Rementer C, Wu M, Buranaphatthana W, Yang H, Scatena M, Giachelli C
    PLoS ONE, 2013-12-27;8(12):e84465.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  17. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function.
    Authors: Charles, Julia F, Hsu, Lih-Yun, Niemi, Erene C, Weiss, Arthur, Aliprantis, Antonios, Nakamura, Mary C
    J Clin Invest, 2012-11-01;122(12):4592-605.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss.
    Authors: Onal M, Xiong J, Chen X, Thostenson J, Almeida M, Manolagas S
    Oncogene, 2012-07-10;287(35):29851-60.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  19. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death.
    Authors: Schrader J, Rennekamp W, Niebergall U, Schoppet M, Jahr H, Brendel MD, Horsch D, Hofbauer LC
    Diabetologia, 2007-04-19;50(6):1243-7.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.
    Authors: Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM, Takahashi N
    J. Immunol., 2007-01-01;178(1):192-200.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  21. Serotonin and fluoxetine modulate bone cell function in vitro.
    Authors: Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, Slordahl K, Tamburstuen MV, Reseland JE, Syversen U
    J. Cell. Biochem., 2006-05-01;98(1):139-51.
    Applications: ELISA (Standard)
  22. JunB as a downstream mediator of PTHrP actions in cementoblasts.
    Authors: Berry JE, Ealba EL, Pettway GJ, Datta NS, Swanson EC, Somerman MJ, McCauley LK
    J. Bone Miner. Res., 2005-11-07;21(2):246-57.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  23. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells.
    Authors: Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA
    Blood, 2004-05-13;104(5):1404-10.
    Applications: ELISA (Standard)
  24. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
    Authors: Cao J, Venton L, Sakata T, Halloran BP
    J. Bone Miner. Res., 2003-02-01;18(2):270-7.
    Applications: Western Blot


  1. This protein datasheet indicates I need to use a cross-linking antibody, Catalog # MAB050, for biological activity. What is this antibody and is it really necessary?

    • The antibody is directed against a 6x histidine repeat and is recommended for use as a cross-linker of proteins with 6x his-tag. Crosslinking is often used for proteins that require receptor trimerization and can result greater biological activity. R&D Systems Quality Control tests the performance of these proteins in the presence of the cross-linking antibody. Therefore, it is necessary to use this antibody when trying to achieve the same level of specific activity described in the datasheet.

View all Proteins and Enzyme FAQs

Reviews for Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF

Average Rating: 5 (Based on 1 Review)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF
By Anonymous on 10/11/2020
Application: In vitro bioactivity in cell culture
Reason for Rating: Using the OPG as a positive control to block RANKL induced the osteoclast differentiation, it works well.